@article{article, title  = {{Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase}},

 publisher = {{Elsevier}},

 url = {{http://eprints.whiterose.ac.uk/163983/ }},

 year = {{2020}},

 month = {{9}},

 author = {{Pivonello R and Fleseriu M and Newell-Price J and Bertagna X and Findling J and Shimatsu A and Gu F and Auchus R and Leelawattana R and Lee EJ and Kim JH et al}},

 doi = {{10.1016/s2213-8587(20)30240-0}},

 volume = {{8}},

 journal = {{The Lancet Diabetes & Endocrinology}},

 issue = {{9}},

 pages = {{748-761}},

 note = {{Accessed on 2024/12/22}}}